Advances in HIV Vaccine
An HIV vaccine can be either a preventive vaccine or a therapeutic vaccine, which means it can either protect individuals from being infected with HIV or treat HIV-infected individuals. And it can either induce an immune response against HIV (active vaccination approach) or consist of preformed antibodies against HIV (passive vaccination approach).There is currently no licensed HIV vaccine on the market, but multiple research projects are trying to find an effective vaccine. Evidence observed from humans shows that a vaccine may be possible: Some, but certainly not all, HIV-infected individuals naturally produce broadly neutralizing antibodies which keep the virus suppressed, and these people remain asymptomatic for decades. Potential broadly neutralizing antibodies have been cloned in the laboratory (monoclonal antibodies) and are being tested in passive vaccination clinical trials.
Components of the Book:
  • Chapter 1
    A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults
  • Chapter 2
    Combining biomedical preventions for HIV Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions
  • Chapter 3
    Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA
  • Chapter 4
    Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low-and Middle-Income Countries
  • Chapter 5
    HIV Epidemic in Asia Implications for HIV Vaccine and Other Prevention Trials
  • Chapter 6
    HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects
  • Chapter 7
    HIV-Exposed Infants Vaccinated with an MF59Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine
  • Chapter 8
    Lessons Learned from HIV Vaccine Clinical Efficacy Trials
  • Chapter 9
    Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa
  • Chapter 10
    Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens
  • Chapter 11
    Preparing for the availability of a partially effective HIV vaccine Some lessons from other licensed vaccines
  • Chapter 12
    Reported willingness to participate in a hypothetical HIV vaccine trial and its translation to actual participation among healthy adults—Experience from Kenya
  • Chapter 13
    Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
  • Chapter 14
    “. . . I’ve Gone Through This My Own Self, So I Practice What I Preach . . . ” Strategies to Enhance Understanding and Other Valued Outcomes in HIV Vaccine Trials in South Africa
  • Chapter 15
    “Why Don’t You Go Into Suburbs Why Are You Targeting Us” Trust and Mistrust in HIV Vaccine Trials in South Africa
Readership: Students, academics, teachers and other people attending or interested in HIV Vaccine.
Janet M McNicholl
Janet M McNicholl a Division of HIV/AIDS, Laboratory Branch , Centers for Disease Control and Prevention , Atlanta , GA , USA.

Blythe Adamson
Blythe Adamson Department of Pharmacy, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA.

Ruanne V Barnabas
Ruanne V Barnabas Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

James Kublin
James Kublin Division of Allergy and Infectious Diseases, Department of Global Health, University of Washington, Seattle, WA, USA.

Thomas M Harmon
Thomas M Harmon International AIDS Vaccine Initiative, New York, NY, United States of America.

John Stover
John Stover Avenir Health, Glastonbury, CT, United States of America.

and more...
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top